



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

May 22, 2025

Scott Giacobello
Chief Financial Officer
Whitehawk Therapeutics, Inc.
2 Headquarters Plaza East Building
11th Floor
Morristown, NJ 07960

Re: Whitehawk Therapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2024
File No. 001-38560

Dear Scott Giacobello:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences